Nalaganje...
Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas
Thymic malignancies are rare tumors of the mediastinum. c-KIT is highly expressed in thymic carcinomas (TC) but infrequently in thymomas. Anecdotal experience suggests activity of imatinib mesylate in TC. Patients with unresectable World Health Organization B3 thymomas or TC, performance status 0 to...
Shranjeno v:
| izdano v: | J Thorac Oncol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2009
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7372705/ https://ncbi.nlm.nih.gov/pubmed/20197733 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181b6be57 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|